Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects

被引:23
作者
Rogers, JF
Nafziger, AN
Kashuba, ADM
Streetman, DS
Rocci, ML
Choo, EF
Wilkinson, GR
Bertino, JS
机构
[1] Basset Healthcare, Clin Pharmacol Res Ctr, Cooperstown, NY 13326 USA
[2] Basset Healthcare, Dept Med, Cooperstown, NY 13326 USA
[3] Basset Healthcare, Dept Pharm Serv, Cooperstown, NY 13326 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] Oneida Res Serv Inc, Pharmaceut & Chem Anal, Whitesboro, NY USA
[7] Vanderbilt Univ, Nashville, TN USA
关键词
D O I
10.1177/009127002401382614
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The 30-minute ratio of 1'-hydroxymidazolam:midazolam plasma concentrations has been used as a measure of midazolam clearance in liver transplant patients. This study determined if a single concentration of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam could be used to predict midazolam clearance in healthy subjects. Plasma midazolam and 1'-hydroxymidazolam concentrations from three previous studies were used for analyses. Data obtained predoseand at 5, 30, 60,120, 240, 300, and 360 minutes following intravenous doses of midazolam in 61 adults were divided and used to derive and validate equations to predict midazolam clearance. Equations were derived using linear regression and then validated by comparing predicted to observed clearance. Only one equation was related to midazolam clearance as a function of 1'-hydroxymidazolam, but it did not predict midazolam clearance (r = 0.29, p = 0.31). Single sampling of 1'-hydroxymidazolam or 1'-hydroxymidazolam:midazolam plasma concentrations cannot be used to predict midazolam clearance in healthy adults.
引用
收藏
页码:1079 / 1082
页数:4
相关论文
共 12 条
[1]   Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-γ agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity [J].
Fayer, JL ;
Zannikos, PN ;
Stevens, JC ;
Luo, YQ ;
Sidhu, R ;
Kirkesseli, S .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (03) :305-316
[2]   Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam [J].
Kashuba, ADM ;
Bertino, JS ;
Rocci, ML ;
Kulawy, RW ;
Beck, DJ ;
Nafziger, AN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :269-277
[3]  
Kim JS, 2000, CLIN PHARMACOL THER, V67, P161
[4]   Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: Application to various assay techniques [J].
Kim, JS ;
Nafziger, AN ;
Tsunoda, SM ;
Choo, EF ;
Streetman, DS ;
Kashuba, ADM ;
Kulawy, RW ;
Beck, DJ ;
Rocci, ML ;
Wilkinson, GR ;
Greenblatt, DJ ;
Bertino, JS .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (04) :376-382
[5]  
*MICROMEDEX, 2002, MICROMEDEXR HEALTHC
[6]   CYP2C19 genotype and phenotype determined by omeprazole in a Korean population [J].
Roh, HK ;
Dahl, ML ;
Tybring, G ;
Yamada, H ;
Cha, YN ;
Bertilsson, L .
PHARMACOGENETICS, 1996, 6 (06) :547-551
[7]   Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism [J].
Sagar, M ;
Tybring, G ;
Dahl, ML ;
Bertilsson, L ;
Seensalu, R .
GASTROENTEROLOGY, 2000, 119 (03) :670-676
[8]   Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes [J].
Streetman, DS ;
Bertino, JS ;
Nafziger, AN .
PHARMACOGENETICS, 2000, 10 (03) :187-216
[9]   Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail" [J].
Streetman, DS ;
Bleakley, JF ;
Kim, JS ;
Nafziger, AN ;
Leeder, JS ;
Gaedigk, A ;
Gotschall, R ;
Kearns, GL ;
Bertino, JS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (04) :375-383
[10]  
THUMMEL KE, 1994, J PHARMACOL EXP THER, V271, P557